PROCEPT BioRobotics (NASDAQ:PRCT) EVP Alaleh Nouri Sells 5,363 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) EVP Alaleh Nouri sold 5,363 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $25.96, for a total value of $139,223.48. Following the sale, the executive vice president owned 105,354 shares in the company, valued at approximately $2,734,989.84. This represents a 4.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alaleh Nouri also recently made the following trade(s):

• On Tuesday, March 17th, Alaleh Nouri sold 304 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $28.15, for a total transaction of $8,557.60.
• On Tuesday, March 10th, Alaleh Nouri sold 3,243 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $25.65, for a total transaction of $83,182.95.
• On Friday, March 6th, Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $23.70, for a total value of $163,340.40.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock opened at $25.73 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.85 and a quick ratio of 5.77. PROCEPT BioRobotics Corporation has a one year low of $19.35 and a one year high of $66.85. The firm has a market cap of $1.45 billion, a PE ratio of -15.05 and a beta of 1.02. The stock’s fifty day moving average price is $28.13 and its two-hundred day moving average price is $32.17.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The firm had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.PROCEPT BioRobotics’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.35) EPS. As a group, research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. UBS Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 target price on the stock. Wells Fargo & Company cut their price objective on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Wall Street Zen lowered PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Bank of America downgraded PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $38.00 to $20.00 in a research note on Thursday, February 26th. Finally, Leerink Partners decreased their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $40.82.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. DNB Asset Management AS purchased a new stake in shares of PROCEPT BioRobotics during the third quarter valued at approximately $1,132,000. Chicago Capital LLC grew its stake in PROCEPT BioRobotics by 175.7% in the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after purchasing an additional 999,873 shares during the period. C WorldWide Group Holding A S purchased a new stake in shares of PROCEPT BioRobotics during the 3rd quarter valued at $5,354,000. Granite Investment Partners LLC purchased a new position in shares of PROCEPT BioRobotics in the 2nd quarter worth about $8,159,000. Finally, Peregrine Capital Management LLC purchased a new position in shares of PROCEPT BioRobotics in the 3rd quarter worth about $6,718,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.